Ω-3 fatty acid supplements for cancer-associated weight loss

Nutrition in Clinical Practice

Volumn 20, Issue 4, 2005, Pages 394-399

  Jatoi, Aminah ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MEDICAL RESEARCH; REVIEW; WEIGHT REDUCTION; CACHEXIA; DRUG EFFECT; EVIDENCE BASED MEDICINE; METABOLISM; NEOPLASM; PRACTICE GUIDELINE;

CACHEXIA; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, OMEGA-3; NEOPLASMS; PRACTICE GUIDELINES; WEIGHT LOSS;

EID: 33644825864     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426505020004394     Document Type: Review

References (22)

1. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients: Eastern Cooperative Oncology Group. Am J Med. 1980;69:491-497.
2. Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism. 1981;30: 222-229.
3. Moore FD. Energy and the maintenance of the body cell mass. JPEN J Parenter Enteral Nutr. 1980;4:228-260.
4. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
5. Holden CM. Anorexia in the terminally ill cancer patient: the emotional impact on the patient and family. Hosp J. 1991;24:73-84.
6. Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med. 2002;16:499-506.
7. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol. 2003;21(suppl 9):79-81.
8. Rosenberg IH. Fish: food to calm the heart. N Engl J Med. 2002;346:1102-1103.
9. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995;268(5 pt 1):E996-E1006.
10. Lazarus DD, Destree AT, Mazzola LM, et al. A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol. 1999;277:E332-E341.
11. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003;237:384-389.
12. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604-3609.
13. Wigmore SJ, Fearon KCH, Maingay JP, Garden OJ, Ross JA. Down regulation of the acute phase response in patients with pancreatic cancer cachexia receiving eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond). 1997; 92:215-221.
14. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996;379: 739-742.
15. Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res. 1999;59: 5507-5513.
16. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized controlled trial. Cancer. 1998;82:395-402.
17. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutrition supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80-86.
18. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. 2003; Gut. 52:1479-1486.
19. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21:129-134.
20. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
21. Burch PA, Block M, Schroeder G, et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Clin Cancer Res. 2000;6:3486-3492.
22. Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11:652-659.